Kopran Ltd
NSE:KOPRAN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Kopran Ltd
NSE:KOPRAN
|
IN |
|
S
|
Salcon Bhd
KLSE:SALCON
|
MY |
Kopran Ltd
Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. The company is headquartered in Mumbai, Maharashtra. The firm is engaged in the business of manufacturing and supplying international formulations (Finished Dosage Form) and active pharmaceutical ingredients (APIs). Its formulation business unit manufactures oral solid dosages and dry powder formulations for both penicillin and non-penicillin-based drugs. Its APIs business unit offers Sterile Cephalosporins and Carbapenems. The company also offers Macrolide, Antibacterial, Anticonvulsant, and Cardiovascular range of drugs. Its product offering includes antibiotics, cardiovascular, antidiabetic, gastrointestinal, pain management, drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, and anthelmintics. Its antibiotics brands include AMPIK 250 / 500, AMPIK SYRUP, and AMYN - 250 / 500. Its cardiovascular brands include CARDIOTEN - 25 / 50 / 100, CADITONE - 3.125 / 6.25 / 12.5 / 25 and KLODIP - 5 / 10.
Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. The company is headquartered in Mumbai, Maharashtra. The firm is engaged in the business of manufacturing and supplying international formulations (Finished Dosage Form) and active pharmaceutical ingredients (APIs). Its formulation business unit manufactures oral solid dosages and dry powder formulations for both penicillin and non-penicillin-based drugs. Its APIs business unit offers Sterile Cephalosporins and Carbapenems. The company also offers Macrolide, Antibacterial, Anticonvulsant, and Cardiovascular range of drugs. Its product offering includes antibiotics, cardiovascular, antidiabetic, gastrointestinal, pain management, drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, and anthelmintics. Its antibiotics brands include AMPIK 250 / 500, AMPIK SYRUP, and AMYN - 250 / 500. Its cardiovascular brands include CARDIOTEN - 25 / 50 / 100, CADITONE - 3.125 / 6.25 / 12.5 / 25 and KLODIP - 5 / 10.
Revenue Growth: Kopran reported revenue of INR 166.24 crores for Q3 FY25, up 9.6% quarter-on-quarter from INR 151.56 crores.
Margin Expansion: EBITDA increased from INR 14.74 crores to INR 22.91 crores, with EBITDA margin rising to 13.78% from 9.7% last quarter.
API Recovery: API segment showed a significant rebound, with revenue up 20% QoQ and EBITDA margin nearly doubling to 11.57%.
Profitability Impacted by ForEx: Net profit rose to INR 10.4 crores (from INR 7.38 crores), despite INR 3.07 crores in ForEx losses this quarter compared to a gain in Q2.
Guidance for Growth: Management expects 15% consolidated revenue growth for FY26 and 20% for FY27, with a target of ~INR 1,200 crores revenue in 3.5 years.
CMO/CDMO Focus: The company is ramping up contract manufacturing projects, aiming for CMO/CDMO to contribute over 50% of business in 2 years.
Margin Outlook: Long-term EBITDA margin expected to settle between 17% and 20%.
